| Autor: |
W J, Rogan, N B, Ragan, A I, Damokosh, C, Davoli, T R, Shaffer, R L, Jones, S, Wilkens, M C, Heenehan, J H, Ware, F, Henretig |
| Rok vydání: |
2004 |
| Zdroj: |
Pharmacoepidemiology and drug safety. 8(5) |
| ISSN: |
1053-8569 |
| Popis: |
The Treatment of Lead-exposed Children (TLC) trial tested whether developmental outcome differed between children treated for lead poisoning with succimer or placebo. On 7 July 1997, TLC was informed that the vitamin and mineral supplements it gave to all children were contaminated with about 35 microg of lead per tablet.TLC recalled the contaminated supplements and measured the children's exposure.The families of 96% of the children were contacted with 30 days. Among the 571 children to whom the contaminated supplements were dispensed, the mean increase in blood lead was 0.06+/-0.01 micromol/L (1.2+/-0.2 microg/dL); among 78 children to whom they were not, it was 0.09+/-0.03 micromol/L (1.8+/-0.7 microg/dL). There was no evidence of a dose-response relation between estimated supplement consumption and increase in blood lead concentration.The children's blood lead concentrations were not detectably affected by the contamination. Since the association of cognitive delay with lead exposure is best described for blood lead, we believe that the trial's inference about the effect of drug therapy on lead induced cognitive delay should be unaffected. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text